http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18779699

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't
endingPage 949
issn 1476-5454
0950-222X
issueIdentifier 7
pageRange 944-949
publicationName Eye (London, England)
startingPage 944
bibliographicCitation Paskowitz DM, Nguyen QD, Gehlbach P, Handa JT, Solomon S, Stark W, Shaikh O, Semba C, Gadek TR, Do DV. Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study. Eye (Lond). 2012 Jul;26(7):944–9. PMID: 22538219; PMCID: PMC3396168.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9223763ecf8aab752f0c3bb8bb22913b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0976b9fcd1d60e64757a022bb77b22d9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_71d248e5df3ea5c1419e41a930af4617
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4d6eb449f283bd2d103b268815140947
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cec64d035f739a5316556c17dd7dd982
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1a11a29f3c5fd30bc8d31063cc1d210f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1ae0206dcc3f24f477287b6e03706cca
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_070c8f21943a947a5c7072ec49874401
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ebf2899e603c45fbdc86e9140c0e2dc1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a670d5932e9d782f83eab71162cd1be3
date 2012-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/PMC3396168
https://doi.org/10.1038/eye.2012.68
https://pubmed.ncbi.nlm.nih.gov/22538219
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/3725
https://portal.issn.org/resource/ISSN/1476-5454
https://portal.issn.org/resource/ISSN/0950-222X
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
https://scigraph.springernature.com/
title Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study
discusses http://id.nlm.nih.gov/mesh/M0015329
http://id.nlm.nih.gov/mesh/M0024683
http://id.nlm.nih.gov/mesh/M0020791
http://id.nlm.nih.gov/mesh/M0588814
http://id.nlm.nih.gov/mesh/M0024736
http://id.nlm.nih.gov/mesh/M0016544
hasSubjectTerm http://purl.org/au-research/vocabulary/anzsrc-for/2008/11
http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7475
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8398
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_9925ec353faa7fa6b759a9d97e0fc13d
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7440
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_1d95d62df86affba92c68aebdb789580
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8173
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7512
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11965427

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127654813

Total number of triples: 48.